一个社区主导的倡议，以降低风险和推进帕金森病的治疗目标

IF 6.7 1区医学 Q1 NEUROSCIENCES

NPJ Parkinson's Disease Pub Date : 2025-06-20 DOI:10.1038/s41531-025-01039-3

Alexandra Vaiana, Jonathan Behr, Ryan Birol, Cornelis Blauwendraat, Bradford Casey, Kushan Chowdhury, Martin Citron, Joshua Crapser, Victoria Dardov, Fiona Ducotterd, Sonya Dumanis, John Dunlop, Michelle Durborow, Brian Fiske, Jessica Golden, Jonas Hannestad, Wendy Hung, Jennifer Kemp, Robin Kleiman, Adam Knight, Andrew Koemeter-Cox, Bruce Leuchter, Bejamin A. Logsdon, Rita Marreiros, Julie E. Miller, Amanda Mitchell, Pooja Mukherjee, Grace Navarro, Matthew R. Nelson, Karoly Nikolich, Tom Otis, Nicole Polinski, Shima Rastegar-Pouyani, Alastair D. Reith, Ekemini Riley, Lee Rubin, Mina Ryten, Jessica Sadick, Tina Schwabe, Todd Sherer, Sarah Silvergleid, Andrew Singleton, Lara St. Clair, Jan Stoehr, David J. Stone, Julianna Sullivan, Nicole Tanenbaum, Elisa Tinelli, Kate Trimble, Yifei Wang, Stacie Weninger, Nicolás Wiggenhauser, Stephen Wood, Darryle Schoepp, Virginie Buggia-Prevot, Shalini Padmanabhan, Gaia Skibinski

{"title":"一个社区主导的倡议，以降低风险和推进帕金森病的治疗目标","authors":"Alexandra Vaiana, Jonathan Behr, Ryan Birol, Cornelis Blauwendraat, Bradford Casey, Kushan Chowdhury, Martin Citron, Joshua Crapser, Victoria Dardov, Fiona Ducotterd, Sonya Dumanis, John Dunlop, Michelle Durborow, Brian Fiske, Jessica Golden, Jonas Hannestad, Wendy Hung, Jennifer Kemp, Robin Kleiman, Adam Knight, Andrew Koemeter-Cox, Bruce Leuchter, Bejamin A. Logsdon, Rita Marreiros, Julie E. Miller, Amanda Mitchell, Pooja Mukherjee, Grace Navarro, Matthew R. Nelson, Karoly Nikolich, Tom Otis, Nicole Polinski, Shima Rastegar-Pouyani, Alastair D. Reith, Ekemini Riley, Lee Rubin, Mina Ryten, Jessica Sadick, Tina Schwabe, Todd Sherer, Sarah Silvergleid, Andrew Singleton, Lara St. Clair, Jan Stoehr, David J. Stone, Julianna Sullivan, Nicole Tanenbaum, Elisa Tinelli, Kate Trimble, Yifei Wang, Stacie Weninger, Nicolás Wiggenhauser, Stephen Wood, Darryle Schoepp, Virginie Buggia-Prevot, Shalini Padmanabhan, Gaia Skibinski","doi":"10.1038/s41531-025-01039-3","DOIUrl":null,"url":null,"abstract":"<p>Identifying effective therapeutic targets for Parkinson’s disease (PD) is challenging, with no current disease-modifying therapies available. To address this, The Michael J. Fox Foundation for Parkinson’s Research launched the Targets to Therapies (T2T) initiative, uniting experts to prioritize and validate promising targets. T2T aims to develop validation strategies, create comprehensive target data profiles, and build tools to support drug development, ultimately accelerating the discovery of new therapies for PD patients.</p>","PeriodicalId":19706,"journal":{"name":"NPJ Parkinson's Disease","volume":"38 1","pages":""},"PeriodicalIF":6.7000,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A community-led initiative to de-risk and advance Parkinson’s disease therapeutic targets\",\"authors\":\"Alexandra Vaiana, Jonathan Behr, Ryan Birol, Cornelis Blauwendraat, Bradford Casey, Kushan Chowdhury, Martin Citron, Joshua Crapser, Victoria Dardov, Fiona Ducotterd, Sonya Dumanis, John Dunlop, Michelle Durborow, Brian Fiske, Jessica Golden, Jonas Hannestad, Wendy Hung, Jennifer Kemp, Robin Kleiman, Adam Knight, Andrew Koemeter-Cox, Bruce Leuchter, Bejamin A. Logsdon, Rita Marreiros, Julie E. Miller, Amanda Mitchell, Pooja Mukherjee, Grace Navarro, Matthew R. Nelson, Karoly Nikolich, Tom Otis, Nicole Polinski, Shima Rastegar-Pouyani, Alastair D. Reith, Ekemini Riley, Lee Rubin, Mina Ryten, Jessica Sadick, Tina Schwabe, Todd Sherer, Sarah Silvergleid, Andrew Singleton, Lara St. Clair, Jan Stoehr, David J. Stone, Julianna Sullivan, Nicole Tanenbaum, Elisa Tinelli, Kate Trimble, Yifei Wang, Stacie Weninger, Nicolás Wiggenhauser, Stephen Wood, Darryle Schoepp, Virginie Buggia-Prevot, Shalini Padmanabhan, Gaia Skibinski\",\"doi\":\"10.1038/s41531-025-01039-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Identifying effective therapeutic targets for Parkinson’s disease (PD) is challenging, with no current disease-modifying therapies available. To address this, The Michael J. Fox Foundation for Parkinson’s Research launched the Targets to Therapies (T2T) initiative, uniting experts to prioritize and validate promising targets. T2T aims to develop validation strategies, create comprehensive target data profiles, and build tools to support drug development, ultimately accelerating the discovery of new therapies for PD patients.</p>\",\"PeriodicalId\":19706,\"journal\":{\"name\":\"NPJ Parkinson's Disease\",\"volume\":\"38 1\",\"pages\":\"\"},\"PeriodicalIF\":6.7000,\"publicationDate\":\"2025-06-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NPJ Parkinson's Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41531-025-01039-3\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Parkinson's Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41531-025-01039-3","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

摘要

确定帕金森病（PD）的有效治疗靶点是具有挑战性的，目前没有可用的疾病修饰疗法。为了解决这一问题，迈克尔·j·福克斯帕金森研究基金会发起了“从目标到治疗”（T2T）倡议，联合专家对有希望的目标进行优先排序和验证。T2T旨在制定验证策略，创建全面的目标数据概况，并建立支持药物开发的工具，最终加速PD患者新疗法的发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

A community-led initiative to de-risk and advance Parkinson’s disease therapeutic targets

查看原文本刊更多论文

A community-led initiative to de-risk and advance Parkinson’s disease therapeutic targets

Identifying effective therapeutic targets for Parkinson’s disease (PD) is challenging, with no current disease-modifying therapies available. To address this, The Michael J. Fox Foundation for Parkinson’s Research launched the Targets to Therapies (T2T) initiative, uniting experts to prioritize and validate promising targets. T2T aims to develop validation strategies, create comprehensive target data profiles, and build tools to support drug development, ultimately accelerating the discovery of new therapies for PD patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

NPJ Parkinson's Disease Medicine-Neurology (clinical)

CiteScore

9.80

自引率

5.70%

发文量

156

审稿时长

11 weeks

期刊介绍： npj Parkinson's Disease is a comprehensive open access journal that covers a wide range of research areas related to Parkinson's disease. It publishes original studies in basic science, translational research, and clinical investigations. The journal is dedicated to advancing our understanding of Parkinson's disease by exploring various aspects such as anatomy, etiology, genetics, cellular and molecular physiology, neurophysiology, epidemiology, and therapeutic development. By providing free and immediate access to the scientific and Parkinson's disease community, npj Parkinson's Disease promotes collaboration and knowledge sharing among researchers and healthcare professionals.